Pyrimidine ether derivatives and methods of use thereof
The present invention relates to Pyrimidine Ether Derivatives, compositions comprising a Pyrimidine Ether Derivative, and methods of using the Pyrimidine Ether Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G-protein coupled receptor (GPCR) in a patient.
1. A compound having the formula:
wherein:
Q is —C(O)O— or a bond;
W is —C(O)—, —C(O)O— or —S(O) 2 —;
Y is halo;
R 3 is alkyl, haloalkyl, cycloalkyl or -alkylene-O-alkyl; and
R 10 is cycloalkyl or heteroaryl, either of which can be substituted with an alkyl or halo group.
2. The compound of claim 1 , wherein W is —C(O)— or —C(O)O—.
3. The compound of claim 1 , wherein W is —S(O) 2 —.
4. The compound of claim 1 , wherein R 3 is methyl, ethyl, n-propyl, isopropyl, t-butyl, —CF 3 , —CH 2 CH 2 OCH 3 , —CH 2 CH 2 CF 3 , cyclopropyl or cyclopentyl.
5. A compound having the structure:
or a pharmaceutically acceptable salt thereof.
6. A composition comprising an effective amount of one or more compounds of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
7. A method for treating diabetes in a patient, the method comprising administering to the patient an effective amount of one or more compounds of claim 1 , or a pharmaceutically acceptable salt thereof.
8. The composition of claim 6 , further comprising at least one additional therapeutic agent, wherein the additional therapeutic agent is selected from an antidiabetic agent and an antiobesity agent.
9. A compound which is:
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1 which is:
or a pharmaceutically acceptable salt thereof.